Current Edition


Pfizer’s Cibinqo snags FDA approval to challenge Sanofi and Regeneron’s Dupixent in eczema

Look out, Sanofi and Regeneron: Pfizer is on the scene in atopic dermatitis with another blockbuster-to-be. Friday, the FDA approved the New York drugmaker’s oral …

Continue Reading →

Sanofi and Regeneron’s Dupixent aces another test, this time in the debilitating itch condition prurigo nodularis

Sanofi and Regeneron have big ambitions for immunology superstar Dupixent—envisioning the potential for $11 billion in annual sales. In acing a test in people with …

Continue Reading →

Amid COVID’s latest surge, Regeneron and Eli Lilly score new antibody supply deals with the U.S.

During a call with analysts last month, Regeneron said it didn’t expect to record additional sales of its COVID-19 antibodies to the United States this …

Continue Reading →